- Home
- MBWM vs ABSI Comparison
MBWM vs ABSI Comparison
Compare MBWM & ABSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MBWM | ABSI |
|---|---|---|
| Founded | 1997 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 997.8M |
| IPO Year | 1997 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MBWM | ABSI |
|---|---|---|
| Price | $60.46 | $9.39 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 4 |
| Target Price | ★ $55.67 | $6.96 |
| AVG Volume (30 Days) | 75.2K | ★ 2.5M |
| Earning Date | 04-21-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.08% | N/A |
| EPS Growth | ★ 10.95 | 10.64 |
| EPS | ★ 2.82 | N/A |
| Revenue | N/A | ★ $4,534,000.00 |
| Revenue This Year | $20.28 | $215.96 |
| Revenue Next Year | $4.67 | $319.10 |
| P/E Ratio | $21.81 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.75 | $2.24 |
| 52 Week High | $62.42 | $12.06 |
Technical Indicators
Market Signals| Indicator | MBWM | ABSI |
|---|---|---|
| Relative Strength Index (RSI) | 55.80 | 40.61 |
| Support Level | $50.02 | $6.69 |
| Resistance Level | $62.39 | $10.03 |
| Average True Range (ATR) | 1.33 | 0.45 |
| MACD | 0.04 | -0.13 |
| Stochastic Oscillator | 67.49 | 11.38 |
Price Performance
Historical ComparisonAbout MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About ABSI Absci Corporation
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process. Its lead product candidate, ABS-201, is an anti-prolactin receptor (PRLR) antibody engineered with an extended half-life to support a patient-friendly dosing interval.